|Bid||18.19 x 800|
|Ask||18.20 x 1200|
|Day's range||18.18 - 18.39|
|52-week range||12.43 - 20.93|
|Beta (5Y monthly)||1.09|
|PE ratio (TTM)||22.45|
|Forward dividend & yield||0.84 (4.61%)|
|Ex-dividend date||30 Mar 2020|
|1y target est||23.60|
Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK), today announced a partnership for the development, manufacturing and commercialization of NVX‑CoV2373, Novavax’ COVID‑19 vaccine candidate, in Japan. NVX‑CoV2373 is a stable, prefusion protein made using Novavax’ recombinant protein nanoparticle technology and includes Novavax’ proprietary Matrix‑M™ adjuvant. Takeda will receive funding from the Government of Japan’s Ministry of Health, Labour and Welfare (MHLW) to support the technology transfer, establishment of infrastructure and scale-up of manufacturing. Takeda anticipates the capacity to manufacture over 250 million doses of the COVID-19 vaccine per year1.
BioLife Plasma Services announces opening of first plasma collection center in Louisiana.
The results provide more justification for the FDA to grant the substance emergency use authorization.